SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
BiotechTV - News
00:00
What the maintenance readout must show
Marc sets success expectations for maintenance: roughly 20–30% placebo-corrected remission and strong safety.
Play episode from 04:15
Transcript
